banner
Archived Content

Fourth Annual
ADJUVANTS & DELIVERY SYSTEMSAugust 15-16, 2012 

Day 1 | Day 2 | Download Brochure 

Adjuvants and Novel Delivery Systems are widely accepted as key to creating more efficacious vaccines with improved methods for storage and delivery. This leading vaccine meeting addresses the ongoing achievements of creating the next generation of vaccines, including toll-like receptor technology and DNA vaccines. Though lack of FDA approval for new adjuvants presents a major hurdle, researchers continue to delineate adjuvants’ mode of action in the quest to improve vaccines for human use. In the Adjuvants & Delivery Systems meeting, vaccine leaders will discuss their innovative work that is creating a new era of advanced vaccines.

WEDNESDAY, AUGUST 15

8:00 am Conference Registration and Morning Coffee


Plenary Session
Vaccinomics: Technologies to Advance Vaccine Development
 

8:50 Chairperson’s Opening Remarks

William M. Egan, Ph.D., Senior Technical Expert, Novartis Vaccines & Diagnostics, Novartis Institutes for BioMedical Research, Inc.


» Keynote Presentation: 

9:00 Systems Vaccinology: Enabling Rational Vaccine Design with Systems Biology 

Bali PulendranBali Pulendran, Ph.D., Professor, Pathology and Laboratory Medicine, Emory University School of Medicine - Biography  

Despite their great success, we understand little about how effective vaccines stimulate protective immune responses. Two recent developments promise to yield such understanding: the appreciation of the crucial role of the innate immune system in sensing microorganisms and tuning immune responses, and advances in systems biology. In this presentation, I will discuss how these developments are yielding insights into the mechanism of some of the most successful vaccines ever developed. Furthermore, such developments promise to address a major challenge in vaccinology: that the efficacy of a vaccine can only be ascertained retrospectively, upon infection. We have recently used a systems biology approach to identify early gene signatures that correlate with, and predict the later immune responses in humans vaccinated with the live attenuated yellow fever vaccine YF-17D, or with the influenza vaccines. I will review these studies, and discuss their broader implications for vaccinology. 

9:40 Vaccinomics: The Role of Immunogenetics in Vaccine Development

Inna OvsyannikovaInna G. Ovsyannikova, Ph.D., Associate Professor, Medicine, Mayo Vaccine Research Group, Mayo Clinic College of Medicine- Biography 

Recent years have witnessed a growing interest in a field of vaccinology that was named vaccinomics. The overall idea behind vaccinomics is to identify genetic and other mechanisms and pathways that determine immune responses, and thereby provide novel candidate vaccine approaches. Considerable data demonstrate that host genetic polymorphisms act as important determinants of innate and adaptive immunity to vaccines. This talk highlights examples of the role of immunogenetics in understanding immune responses to vaccination, which are highly variable across the population. The influence of HLA genes, non-HLA genes in inter-individual variations in immune responses to viral vaccines are examined using population-based gene/SNP association studies. The ability to understand relationships between immune response gene variants and vaccine-specific immunity may assist in designing new vaccines.

10:15 Reverse Vaccinology: An Evolving Approach in Vaccine Discovery and Development

Fabio BagnoliFabio Bagnoli, Ph.D., Project Leader, Novartis Vaccines & Diagnostics - Biography 

Vaccine research and development are experiencing a renaissance of interest from the global scientific community. There are three major reasons for this: (1) the lack of efficacious treatment for many devastating infections; (2) the emergence of multidrug resistant bacteria, and (3) the great promise for innovative vaccine design and research with convergence of genomics, proteomics, immunomics, and more recently, structural biology and systems biology.  Our first project based on genomics was initiated in 2000 and was termed reverse vaccinology.  At that time, antigen identification was mainly based on bioinformatic analysis of a singular genome.  The first reverse vaccinology-derived vaccine is now in late-stage clinical trials and several novel vaccine candidates are in preclinical studies.  In the meantime, vaccine discovery and development has been further improved with the support of proteomics, functional genomics, comparative genomics, structural biology and systems biology. Furthermore, high-throughput sequencing techniques, unlimited computing resources, as well as new bioinformatics algorithms are now changing the way we perform genomic studies.
Vaccines have enormously contributed to improving health and increasing longevity of human beings. However, infectious diseases are still among the leading cause of death and morbidity worldwide. One of the main factors associated with this unpleasant scenario is the emergence of multi-drug resistant bacteria for which no vaccines are available, such as Staphylococcus aureus.  In order to identify an efficacious vaccine against this complex pathogen, we have used a manifold antigen selection approach which has led to the identification of a tetravalent combination highly protective in animal models of staphylococcal infection.

10:45 Coffee Break with Poster and Exhibit Viewing

11:30 Panel Discussion:   Vaccinomics: Technologies to Advance Vaccine Development

 

William EganModerated by:
William M. Egan, Ph.D., Senior Technical Expert, Novartis Vaccines & Diagnostics, Novartis Institutes for BioMedical Research, Inc.

 

Panelists:

 

Bali Pulendran, Ph.D., Professor, Pathology and Laboratory Medicine, Emory University School of Medicine

 

Inna G. Ovsyannikova, Ph.D., Associate Professor, Medicine, Mayo Vaccine Research Group, Mayo Clinic College of Medicine

 

Fabio Bagnoli, Ph.D., Project Leader, Novartis Vaccines & Diagnostics

 

12:15 pm End of Novel Vaccines. Enjoy Lunch on Your Own

 

Creating Next-Generation Vaccines 

1:40pm Chairperson’s Remarks

Murali Bilikallahalli, Ph.D., Vaccines Formulation and Development, MedImmune LLC


» Opening Keynote Presentation: 

1:45 Opportunities and Challenges for New Vaccines 

Andrew Bett Andrew J. Bett, Ph.D., Senior Research Fellow, Vaccine Research, Merck & Co., Inc. - Biography 

There are still many diseases that require new vaccines. Some of these have been studied for many years while others have emerged more recently. There is a role for both traditional and new technologies for developing new vaccines. The combination of these approaches offers opportunities to discover new vaccines that can further eliminate human infectious disease. 

2:25 Featured Presentation:
DNA Vaccine Enhanced with an Electrical Current

Bjarne BogenBjarne Bogen, Ph.D., Professor of Medicine, Immunology, University of Oslo - Biography 

We have constructed bivalent vaccine fusion proteins that target large antigens to antigen presenting cells. The vaccines are delivered as DNA with an electrical pulse. Transfected cells secrete proteins that target antigen to APC for induction of rapid and enhanced B and T cell responses. A single injection of the vaccine induces antibody-mediated protection against influenza virus within 8 days. Targeted DNA vaccines induce increased antibody responses in larger animals.

Mucosis 3:00 Bacterium-Like Particles and their Role in Mucosal VaccinesBert Jan Haijema, Ph.D., Preclinical Development Director, Mucosis BVMucosis B.V. is a Dutch biotechnology company with a proprietary platform technology, Mimopath™, on which it develops mucosal vaccines with improved efficacy. Mucosis’s lead products are SynGEM™, a vaccine to prevent RSV viral infection, and FluGEM™, a vaccine to prevent influenza. Mimopath™ -based vaccines can be administered needle-free in the nose and mouth, evoking a more natural immune response with a broader base of protection.

3:30 Refreshment Break with Poster and Exhibit Viewing 

4:15 Manufacture, Formulation, Characterization, and Release of a Mixed CpG/Alum Adjuvant for a Phase 1 Vaccine Program

John AmeryJohn Amery, Ph.D., Senior Principal Scientist, Analytical Research and Development, Pfizer BioTherapeutics Pharmaceutical Sciences

CpG DNA was manufactured using standard phosphoramidite chemistry. This CpG was formulated with alum under conditions that maintained the stability of the CpG, created a strong association of the CpG with the alum, and allowed the suspension to be easily re-suspended. The resulting material was filled into vials to support bedside mixing of Adjuvant Product with Drug (antigen) Product at the clinic. The quality of the material was evaluated with appropriate characterization and release testing to ensure it’s acceptability for Phase 1 EMEA and FDA authorized clinical trials.

4:45 Non-Viral Delivery of Self-Amplifying RNA Vaccines

Andrew GeallAndrew Geall, Ph.D., RNA Vaccine Platform Leader, Novartis Vaccines and Diagnostics - Biography 

Novartis has developed a self-amplifying mRNA (SAM™) vaccine platform. The Platform takes advantage of cell-free RNA production from a transcription reaction and delivery with a synthetic delivery system. The broad utility of this novel vaccine technology has been demonstrated with genes encoding antigens from several pathogens and found to elicit broad and potent protective immune responses. Responses are comparable to a viral delivery technology, but without the inherent limitations of viral vectors.

5:15 Reception with Poster and Exhibit Viewing

6:30 Close of Day



Day 1 | Day 2 | Download Brochure